FindTrial
Sign In

Collection of kidney and eye related clinical data to assess the association between diabetes related complications in eye and the kidney in diabetic population using artificial intelligence

Retrospective Collection and Analysis of Nephrology and Ophthalmology Clinical Data to assess the relationship of Diabetic Nephropathy and Diabetic Retinopathy and the prospect of developing predictive Machine Learning Algorithms in Diabetic population.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035391
Enrollment
1200
Registered
2021-08-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications Health Condition 2: E113- Type 2 diabetes mellitus with ophthalmic complications

Interventions

None listed

Sponsors

Carl Zeiss India Bangalore Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Type 1 or type 2 diabetes mellitus who had undergone diabetic nephropathy management with diabetic retinopathy evaluation

Exclusion criteria

Exclusion criteria: 1. Patients less than 18 years of age 2. Non-Diabetic Subjects 3. Patients with no follow up data

Design outcomes

Primary

MeasureTime frame
To collect and analyse the retrospective nephrology and ophthalmology clinical data to assess the relationship of diabetic nephropathy with diabetic retinopathy in diabetic populationTimepoint: The primary outcome will be assessed at baseline parameters (which refers to the data from the first time stamp), and at follow up parameters which might range from a period of 1 year upto 5 years—

Secondary

MeasureTime frame
To assess the possibility of developing predictive machine learning algorithms for diabetic population with diabetic nephropathy or diabetic retinopathyTimepoint: The secondary outcome, that is the developed algorithm will assess the disease association at following time points: Baseline (which refers to the data from the first time stamp), and at follow up which might range from a period of 1 year upto 5 years—

Countries

India

Contacts

Public ContactDr T C Ganesh Babu

Carl Zeiss India (Bangalore) Pvt Ltd

ganesh.babu@zeiss.com9880225622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026